Contract Pharma Manufacturing News

  1. AGC Biologics To Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance 5/28/2026

    AGC Biologics to provide process development and GMP manufacturing for a novel therapy, leveraging its global microbial network across Germany and Japan.

  2. Innovent Biologics And Pfizer Enter Global Strategic Collaboration To Accelerate Development Of Innovative Oncology Medicines 5/28/2026

    Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines.

  3. Eckert & Ziegler Enters Partnership With Thor Medical To Enable Access Of Lead-212 For The Pharmaceutical Industry 5/28/2026

    Eckert & Ziegler SE, a world-leading specialist in isotope-related components, equipment and services for nuclear medicine and radiation therapy, today signed a collaboration and supply agreement with Thor Medical, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment. 

  4. Minaris Expands Rapid Mycoplasma Detection Services With bioMérieux's BIOFIRE® Platform To Reduce Turnaround Time For Release And In-Process Testing 5/27/2026

    Minaris Advanced Testing now offers an additional rapid PCR mycoplasma testing method to support accelerated lot release for advanced therapies and reduce overall development and manufacturing timelines.

  5. CGBIO Signs Global Clinical And Exclusive Commercialization Agreement For NOVOSIS In The U.S., Canada And Australia 5/27/2026

    CGBIO, a regenerative medicine company (CEO: Hyunseung Yu), announced that it has entered into a global clinical development and exclusive commercialization agreement with DePuy Synthes, a global orthopaedics solutions company, for the NOVOSIS bone graft substitute product portfolio in the United States, Canada, and Australia.

  6. CPC Biotech Collaborates With Multiply Labs To Advance Cell Therapy Automation 5/27/2026

    CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processing, has collaborated with Multiply Labs to rapidly advance the use of robotic systems in cell therapy manufacturing.

  7. Aptevo And Niowave Launch Strategic Collaboration For Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave At Closing 5/27/2026

    Aptevo Therapeutics Inc., a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, and Niowave, Inc., a leader in radioisotope production and supply with established partnerships across the radiopharmaceutical ecosystem, today announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs.

  8. Minaris Expands Rapid Mycoplasma Detection Services With bioMérieux's BIOFIRE® Platform To Reduce Turnaround Time For Release And In-Process Testing 5/27/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced an expanded rapid mycoplasma testing capability within its Minaris Advanced Testing division through the implementation of bioMérieux's BIOFIRE® Mycoplasma platform.

  9. CordenPharma Acquires AmbioPharm To Expand Global Peptide API Capacity 5/27/2026

    CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), today announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO.

  10. Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate OP-3136 In Combination With NUBEQA® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer 5/26/2026

    Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced a clinical trial collaboration and supply agreement with Bayer AG (“Bayer”) to evaluate OP-3136, Olema’s investigational lysine acetyltransferase 6 (KAT6) inhibitor, in combination with NUBEQA® (darolutamide), Bayer’s androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC).